Literature DB >> 15470160

Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes.

Hiroyuki Yamanaka1, Miki Nakajima, Miki Katoh, Ayano Kanoh, Osamu Tamura, Hiroyuki Ishibashi, Tsuyoshi Yokoi.   

Abstract

Trans-3'-hydroxycotinine is a major metabolite of nicotine in humans and is mainly excreted as O-glucuronide in smoker's urine. Incubation of human liver microsomes with UDP-glucuronic acid produces not only trans-3'-hydroxycotinine O-glucuronide but also N-glucuronide. The formation of N-glucuronide exceeds the formation of O-glucuronide in most human liver microsomes, although N-glucuronide has never been detected in human urine. Trans-3'-hydroxycotinine N-glucuronidation in human liver microsomes was significantly correlated with nicotine and cotinine N-glucuronidations, which are catalyzed mainly by UDP-glucuronosyltransferase (UGT)1A4 and was inhibited by imipramine and nicotine, which are substrates of UGT1A4. Recombinant UGT1A4 exhibited substantial trans-3'-hydroxycotinine N-glucuronosyltransferase activity. These results suggest that trans-3'-hydroxycotinine N-glucuronidation in human liver microsomes would be mainly catalyzed by UGT1A4. In the present study, trans-3'-hydroxycotinine O-glucuronidation in human liver microsomes was thoroughly characterized, since trans-3'-hydroxycotinine O-glucuronide is one of the major metabolites of nicotine. The kinetics were fitted to the Michaelis-Menten equation with a K(m) of 10.0 +/- 0.8 mM and a V(max) of 85.8 +/- 3.8 pmol/min/mg. Among 11 recombinant human UGT isoforms expressed in baculovirus-infected insect cells, UGT2B7 exhibited the highest trans-3'-hydroxycotinine O-glucuronosyltransferase activity (1.1 pmol/min/mg) followed by UGT1A9 (0.3 pmol/min/mg), UGT2B15 (0.2 pmol/min/mg), and UGT2B4 (0.2 pmol/min/mg) at a substrate concentration of 1 mM. Trans-3'-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7 increased with an increase in the substrate concentration up to 16 mM (10.5 pmol/min/mg). The kinetics by recombinant UGT1A9 were fitted to the Michaelis-Menten equation with K(m) = 1.6 +/- 0.1 mM and V(max) = 0.69 +/- 0.02 pmol/min/mg of protein. Trans-3'-hydroxycotinine O-glucuronosyltransferase activities in 13 human liver microsomes ranged from 2.4 to 12.6 pmol/min/mg and were significantly correlated with valproic acid glucuronidation (r = 0.716, p < 0.01), which is catalyzed by UGT2B7, UGT1A6, and UGT1A9. Trans-3'-hydroxycotinine O-glucuronosyltransferase activity in human liver microsomes was inhibited by imipramine (a substrate of UGT1A4, IC(50) = 55 microM), androstanediol (a substrate of UGT2B15, IC(50) = 169 microM), and propofol (a substrate of UGT1A9, IC(50) = 296 microM). Interestingly, imipramine (IC(50) = 45 microM), androstanediol (IC(50) = 21 microM), and propofol (IC(50) = 41 microM) also inhibited trans-3'-hydroxycotinine O-glucuronosyltransferase activity by recombinant UGT2B7. These findings suggested that trans-3'-hydroxycotinine O-glucuronidation in human liver microsomes is catalyzed by mainly UGT2B7 and, to a minor extent, by UGT1A9.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15470160     DOI: 10.1124/dmd.104.001701

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

2.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Authors:  Gang Chen; Nino E Giambrone; Douglas F Dluzen; Joshua E Muscat; Arthur Berg; Carla J Gallagher; Philip Lazarus
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Authors:  Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

4.  Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males.

Authors:  Andy Z X Zhu; Lisa S Cox; Jasjit S Ahluwalia; Caroline C Renner; Dorothy K Hatsukami; Neal L Benowitz; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2015-05       Impact factor: 2.089

5.  Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.

Authors:  Gang Chen; Nino E Giambrone; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

6.  Meconium nicotine and metabolites by liquid chromatography-tandem mass spectrometry: differentiation of passive and nonexposure and correlation with neonatal outcome measures.

Authors:  Teresa R Gray; Raquel Magri; Diaa M Shakleya; Marilyn A Huestis
Journal:  Clin Chem       Date:  2008-10-09       Impact factor: 8.327

7.  Genetic influences on individual differences in nicotine glucuronidation.

Authors:  Christina N Lessov-Schlaggar; Neal L Benowitz; Peyton Jacob; Gary E Swan
Journal:  Twin Res Hum Genet       Date:  2009-10       Impact factor: 1.587

8.  Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoforms.

Authors:  Tiby B Joseph; Stephen W J Wang; Xing Liu; Kaustubh H Kulkarni; Jingrong Wang; Haiyan Xu; Ming Hu
Journal:  Mol Pharm       Date:  2007 Nov-Dec       Impact factor: 4.939

Review 9.  Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism.

Authors:  Yadira X Perez-Paramo; Philip Lazarus
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-12-29       Impact factor: 4.481

10.  Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.

Authors:  Andy Z X Zhu; Qian Zhou; Lisa Sanderson Cox; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.